Currently, cancer is a disease that requires special attention since it is not curable in all cases. However, scientists are developing new epigenetic drugs, which include HDAC inhibitors. The mechanism of action of pills is that they deactivate checkpoints during the cell cycle when cancer cells increase. The role of inhibitors is to suppress protein synthesis and redirect its accumulation to cancer cells (Ghasemi, 2019). This helps trigger a reaction in cancer cells after undergoing chemotherapy. Instead of reactivating at previously delayed checkpoints, cancer cells die. In addition, HDAC inhibitors can provide significant support in the DNA repair process of cells. Since these cells are damaged during cancer, inhibitors partially reverse the process, making the cancer cells more amenable to being killed by chemotherapy.
At this stage of the use of drugs, it is not easy to talk about their effectiveness. Inhibitors continue to be used cautiously; more research is needed. However, HDAC is required to enhance cancer cells’ response to chemotherapy courses and prevent them from returning to checkpoints (Ghasemi, 2019). The drugs can change the protein structure and read the networks of genes faster, which is necessary to treat the disease successfully. In this case, healthy and non-harmful cells have a greater chance of survival, which directly affects the recovery of the body.
References
Ghasemi, S. (2019). Cancer’s epigenetic drugs: where are they in the cancer medicines? The Pharmacogenomics Journal, 20(3), 367–379. Web.